Abstract:Abstract Purpose: Neoadjuvant chemotherapy may provide early indication of treatment response. Pathologic complete response (pCR) rate is a surrogate measure of disease-free and overall survival. Anthracycline remain an important component of chemotherapy regimen for breast cancer (BC), while adding taxane confers additional pCR rate. However the combination of anthracycline and trastuzumab remain controversial due to potential increased risk of cardiac event. This trial was designed to compare the efficacy and safety between epirubicin(E) and carboplatin(C) in combination with paclitaxel(P) and trastuzumab(H). Methods: In 13 medical centers, 100 Patients with HER-2/neu immunohistochemistry (IHC) 3+ or FISH-amplified untreated breast cancer, baseline left ventricular ejection fraction (LVEF) of ≥ 55%, ECOG0/1, were enrolled from Sep 2011 to May 2012. Study medication was as follows: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg) and Pacitaxel (75 mg/m2) weekly combine with Carbopatin (AUC 2) weekly for PCH group or Epirubicin(75 mg/m2) every 3 weeks for PEH group. Patients were recommended to receive 4 or more cycles. The primary endpoint was pCR in the breast and axilla. Secondary endpoints included clinical response, safety. Results: By Aug 16, 2012, 50 patients were randomly assigned to receive PCH regimen and 50 to receive PEH regimen. 49 belonged to TNM stage II, 51 belonged to TNM stage III. The median age was 48 years (range 29 to 65 years). 87 patients completed at least 4 cycles neoadjuvant therapy and then received surgical treatment. pCR in the breast/axilla were found in 38 patients (43.7%; 95% confidence interval [CI]: 33.3%-54.1%). There was no statistic significant difference in PCH and PEH regimen (39.1% vs. 48.8%; p = 0.365). However, PEH regimen achieved significant higher pCR in luminal-B (HER2-poitive) subgroup compared with PCH regimen (55.0% vs. 24.0%; p = 0.033), but not in ERBB2+ subgroup (42.9% vs. 57.1%; p = 0.355). Median LVEF at baseline was 66.0% (range 56.5% to 83.0%), having was no difference between PCH and PEH group (67.0% vs. 65.0%). After 2 cycles in 82 patients, the median LVEF was 64.7% (range 55.0% to 84.0%), there was no difference of LVEF (63.0% vs.66.0%). After 4 cycles in 80 patients, the median LVEF was 66.0% (range 53.0% to 76.0%), no difference was observed between PCH and PEH group (63.0% vs. 66.2%). 8 patients had LVEF decreases of over 10% after 2 cycles, of which 5 patients in PCH group and 3 patients in PEH group. After more than 4 cycles, 3 patients in PCH group and 1 patient in PEH group had LVEF decreases of over 10.0% compared with baseline. No patient experienced LVEF of less than 50% and congestive heart failure (CHF). There was no cardiac death reported. Conclusion: Both PCH and PEH regimens as neoadjuvant chemotherapy have the similar pCR rate for breast cancer patients with HER2-overexpression. PEH might improve the possibility of eradicating invasive cancer in the breast and axilla, especially in the luminal-B (HER2-positive) subtype. PEH is feasible and is not likely to increase the incidence of acute cardiac events compared to PCH. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-17.

A Single-Center, Randomized, Parallel Controlled Study Comparing the Efficacy and Safety Aspects of Three Anthracycline-Based Regimens As Neoadjuvant Chemotherapy in Primary Breast Cancer

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Comparable Efficacy and Less Toxicity of Pegylated Liposomal Doxorubicin Versus Epirubicin for Neoadjuvant Chemotherapy of Breast Cancer: a Case-Control Study

Clinical Study of Different Regimens As Neoadjuvant Chemotherapy for Local Advanced Breast Cancer

Evaluation of adverse effects induced by three different regimens used as neoadjuvant chemotherapy for local advanced breast cancer

A Multicentric Prospective Study of the Effect of Neoadjuvant Chemotherapy with Cyclophosphamide,Fluorouracil and Pirarubicin on Localy Advanced Breast Cancer

Anthracycline-free or Short-Term Regimen As Adjuvant Chemotherapy for Operable Breast Cancer: A Phase III Randomized Non-Inferiority Trial

Regimen Containing with High-Dose Epirubicin, Cyclophosphamide and Fluorouracil As Neoadjuvant Chemotherapy in the Treatment of Breast Cancer

Efficacy and Safety of Neoadjuvant Therapy for HER2-positive Early Breast Cancer: a Network Meta-Analysis

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer

[Clinical Evaluation of Effects from Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel in Cases of Locally Advanced Breast Cancer--comparative Study of Treatment with 2 and 4 Cycles].

Efficacy Analysis of Neoadjuvant Chemotherapy with or Without Anthracyclines in Female Patients with HER2-positive Breast Cancer in China: a Nationwide, Multicenter, 10-Year Retrospective Study (Csbrs-012)

Evaluation of Two Different Regimens As Neoadjuvant Chemotherapy for Breast Cancer

Abstract P4-12-17: Pathological responses and heart safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy in clinical stage II-III, HER2-positive breast cancer patients: A phase 2, open-label, multicentre, randomised trial

Efficacy and safety of different regimens of neoadjuvant chemot h erapy for breast cancer

The Efficacy of Anthracycline-Based Neoadjuvant Chemotherapy in Patients with Breast Cancer

Efficacy And Safety Analysis Of Trastuzumab And Paclitaxel Based Regimen Plus Carboplatin Or Epirubicin As Neoadjuvant Therapy For Clinical Stage Ii-Iii, Her2-Positive Breast Cancer Patients: A Phase 2, Open-Label, Multicenter, Randomized Trial

Efficacy Analysis of THP-containing Regimens As Neoadjuvant and Adjuvant Chemotherapy for Primary Breast Cancer

Anthracycline-containing Versus Carboplatin-Containing Neoadjuvant Chemotherapy in Combination with Trastuzumab for HER2-positive Breast Cancer: the Neocarh Phase II Randomized Clinical Trial.

Comparison of Different Adjuvant Therapy after Radical Surgery in Early Stage Cervical Carcinoma: A 3-Arm Randomized Control Study.

A Prospective Randomized Controlled Study on Multiple Neoadjuvant Treatments for Patients with Stage IB2 to IIA Cervical Cancer